Liberty Global Ltd Class C vs Zimmer Biomet Holdings Inc — how do they compare? Liberty Global Ltd Class C trades at $9.98 (market cap $3.48B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 5.3× Liberty Global Ltd Class C's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| LBTYK | ZBH | |
|---|---|---|
Market Cap | $3.48B | $18.55B |
Sector | Technology | Health |
52-Week High | $12.67 | $107.71 |
52-Week Low | $9.59 | $79.58 |
Enterprise Value | $10.13B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $10.24, down 2.38% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for a 2027 Ziggo Group listing, a key strategic move.
Despite deep losses, the stock appears undervalued on price-to-sales (0.7) and price-to-book (0.37) metrics. Analyst sentiment is strongly bullish (69% buy ratings), seeing upside from asset monetization and the Ziggo spin-off. Key risks include persistent negative margins and execution of the separation plan.
No Aura AI signal available yet.
Trailing returns across standard periods
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →